Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTGJVQM)

• DTT Name: Fibroblast growth factor receptor 2 (FGFR2) DTT Info
• UniProt ID: FGFR2_HUMAN
• Gene Name: FGFR2

Molecule-Related Drug & Molecule List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Interferon Alfa-2a, Recombinant	DMUTZ8S	Chronic HCV-1 infection	1E51.1	Approved	[1]
Palifermin	DM9JOYP	Oral mucositis	DA01.11	Approved	[2]
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[3]

9 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
Trafermin	DMLKI2B	Periodontitis	DA0C	Phase 3	[5]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
LY2874455	DMZ0DMY	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
AEE-788	DMEOS5K	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[9]
Alofanib	DMIEKTF	Gastric adenocarcinoma	2B72	Phase 1	[10]
BAY1179470	DM7L91K	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
RLY-4008	DM3O52N	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PD-0183812	DMWYP86	Retinoblastoma	2D02.2	Terminated	[13]

6 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACTB-1003	DMPHSU8	Solid tumour/cancer	2A00-2F9Z	Investigative	[14]
Anti-FGFR2 humanized mab	DMMQ3WX	Solid tumour/cancer	2A00-2F9Z	Investigative	[14]
PK 11195	DMDOZPU	Discovery agent	N.A.	Investigative	[1]
Platelet factor 4 (PF-4)	DMV34O2	Discovery agent	N.A.	Investigative	[15]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[16]
TG-100435	DMIR3X2	Discovery agent	N.A.	Investigative	[17]

References

• [1] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [2] Keratinocyte growth factor. Expert Opin Biol Ther. 2009 Jun;9(6):779-87.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [4] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [5] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Company report (Eli Lilly) (drug: LY2874455)
• [8] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [9] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [10] Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28]. Eur J Cancer. 2017 Jan;70:156.
• [11] National Cancer Institute Drug Dictionary (drug id 751593).
• [12] Clinical pipeline report, company report or official report of Relay Therapeutics.
• [13] Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1809).
• [15] A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J. 2001 Mar;15(3):550-2.
• [16] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [17] Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.